Blog

Psilocybin and many other psychedelics are broadly prohibited under federal law. But US researchers at the PNI's Pacific Treatment & Research In Psychedelics (TRIP) program have been legally scrutinizing their use in a score of clinical trials.

At Pacific Neuroscience Institute® (PNI) we achieved many milestones in 2022 and continue to make positive impacts in neuroscience clinical care, research, and education.

After a decades-long pause, psychedelics are once again being investigated for their transdiagnostic treatment potential. Discover the future of psychedelics in neurosurgery and neuro-oncology with experts from Pacific Neuroscience Institute ® (PNI).

Ketamine is approved for use at high doses as an anesthetic in the operating room. Although not FDA-approved, lower dose “sub-anesthetic” ketamine injections are used “off-label” to treat depression, pain, and other mental health/substance use disorders.  In recent times, there have been many factors contributing...

Pacific Neuroscience Institute teams in Neurology and Neurosurgery contribute to High Performing Hospitals in US News & World Report rankings.

This year, six of Pacific Neuroscience Institute’s physicians were included in Los Angeles Magazine’s April 2022 roster of “L.A.’s Top Doctors.”

Pacific Neuroscience Institute (PNI) located at Providence Saint John's Health Center, has activated a new psilocybin clinical trial and has begun participant enrollment.

At Pacific Neuroscience Institute, we are looking forward to what lies ahead with fresh excitement. Neurological diseases do not stop and neither have we.

Clinical trials are research studies that play a critical role in the advancement of clinical and medical knowledge about disease. At Pacific Neuroscience Institute (PNI), there are a number of upcoming and ongoing trials for patients with various neurological conditions.

Pacific Neuroscience Institute announces an exciting brain health CME course for practicing clinical professionals. Registration is open.